Research Reports

Key takeaways

CEO Richard Gelfond is on temporary medical leave of absence as previously announced on March 30, 2026.

Robert D. Lister, the Chief Legal Officer and Senior Executive Vice President, was appointed interim principal executive officer effective April 16, 2026.

Mr. Lister will serve as interim PEO until May 1, 2026, after which Mr. Gelfond will resume the role.

No additional compensation will be provided to Mr. Lister for his interim appointment.

The company has not entered into any new compensatory arrangements in connection with this appointment.

Full analysis

The appointment of Robert D. Lister as interim principal executive officer represents a temporary leadership transition while CEO Richard Gelfond is on medical leave. As the company's Chief Legal Officer and Senior Executive Vice President, Mr. Lister brings existing institutional knowledge to the interim role, which should help maintain continuity during this period. The structured timeline with Mr. Gelfond expected to resume his duties on May 1, 2026, provides clarity to investors about the temporary nature of this arrangement. The absence of additional compensation for Mr. Lister's interim duties and the lack of new compensatory arrangements indicate the company is treating this as a temporary administrative matter rather than a permanent leadership change.

IMAX · IMAX Corporation

Summary

Key takeaways

Full analysis